Prognostic value of tumour associated antigen immunoreactivity and apoptosis in cerebral glioblastomas: an analysis of 168 cases

A Korshunov, A Golanov, R Sycheva and I Pronin
Department of Neuropathology, Neurosurgical NN Burdenko Institute, Moscow, Russia. akorshunov@nsi.ru

AIMS: To evaluate a possible association between clinical outcome in patients with glioblastoma and expression of some immunohistochemical variables and apoptosis. METHODS: 168 selected patients with cerebral glioblastomas were studied retrospectively. Tumour specimens were examined immunohistochemically with antibodies to proliferating cell nuclear antigen (PCNA), p53, bcl-2, and epidermal growth factor receptor (EGFR) to detect the intracellular receptor domain. Apoptosis was detected by in situ end labelling. Multivariate analysis was performed using the Cox proportional hazard model. RESULTS: On univariate analysis the PCNA labelling index, immunoexpression of EGFR, and the apoptotic index were significantly related to glioblastoma outcome. Survival time was reduced as PCNA labelling index increased and apoptotic index decreased (p = 0.0073 and p = 0.00031, respectively). Survival time in patients with EGFR positive tumours was found to be reduced (p = 0.00024). Multivariate analysis showed independent prognostic value for the EGFR positivity and apoptotic index only (p = 0.0053 and p = 0.0039, respectively). There was no association between clinical outcome of glioblastoma and p53 or bcl-2 immunostaining. CONCLUSIONS: EGFR immunoreactivity and apoptotic index were found to be useful for assessing prognosis of individual glioblastomas but it seems unlikely that p53 and bcl-2 immunohistochemistry will be of value in determining survival in such patients.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Mangiola, A., Lama, G., Giannitelli, C., De Bonis, P., Anile, C., Lauriola, L., La Torre, G., Sabatino, G., Maira, G., Jhanwar-Uniyal, M., Sica, G. (2007). Stem Cell Marker Nestin and c-Jun NH2-Terminal Kinases in Tumor and Peritumor Areas of Glioblastoma Multiforme: Possible Prognostic Implications. Clin. Cancer Res. 13: 6970-6977 [Abstract] [Full Text]  
• Krex, D., Klink, B., Hartmann, C., von Deimling, A., Pietsch, T., Simon, M., Sabel, M., Steinbach, J. P., Heese, O., Reifenberger, G., Weller, M., Schackert, G., for the German Glioma Network, (2007). Long-term survival with glioblastoma multiforme. Brain 130: 2596-2606 [Abstract] [Full Text]  
• Nafe, R., Franz, K., Schlote, W., Schneider, B. (2005). Morphology of Tumor Cell Nuclei Is Significantly Related with Survival Time of Patients with Glioblastomas. Clin. Cancer Res. 11: 2141-2148 [Abstract] [Full Text]  
• Stoica, G., Kim, H.-T., Hall, D. G., Coates, J. R. (2004). Morphology, Immunohistochemistry, and Genetic Alterations in Dog Astrocytomas. Vet Pathol 41: 10-19 [Abstract] [Full Text]  
• Kuriyama, H., Lamborn, K. R., O'Fallon, J. R., Iturria, N., Sebo, T., Schaefer, P. L., Scheithauer, B. W., Buckner, J. C., Kuriyama, N., Jenkins, R. B., Israel, M. A. (2002). Prognostic significance of an apoptotic index and apoptosis/proliferation ratio for patients with high-grade astrocytomas. Neuro Oncol Duke 4: 179-186 [Abstract]  
• Hara, A, Saegusa, M, Mikami, T, Okayasu, I (2001). Loss of DCC expression in astrocytomas: relation to p53 abnormalities, cell kinetics, and survival. J. Clin. Pathol. 54: 860-865 [Abstract] [Full Text]  
• Chakravarti, A., Delaney, M. A., Noll, E., Black, P. McL., Loeffler, J. S., Muzikansky, A., Dyson, N. J. (2001). Prognostic and Pathologic Significance of Quantitative Protein Expression Profiling in Human Gliomas. Clin. Cancer Res. 7: 2387-2395 [Abstract] [Full Text]  
• Luwor, R. B., Johns, T. G., Murone, C., Huang, H-J. S., Cavenee, W. K., Ritter, G., Old, L. J., Burgess, A. W., Scott, A. M. (2001). Monoclonal Antibody 806 Inhibits the Growth of Tumor Xenografts Expressing Either the de2-7 or Amplified Epidermal Growth Factor Receptor (EGFR) but not Wild-Type EGFR. Cancer Res. 61: 5355-5361 [Abstract] [Full Text]  
• Geiger, K. D., Stoldt, P., Schlote, W., Derouiche, A. (2000). Ezrin Immunoreactivity Is Associated with Increasing Malignancy of Astrocytic Tumors but Is Absent in Oligodendrogliomas. Am. J. Pathol. 157: 1785-1793 [Abstract] [Full Text]